Mechanism of action
Jivi is a site-specific, PEGylated, B-domain deleted, recombinant FVIII with an extended half-life1*
- Jivi temporarily replaces the missing endogenous FVIII needed for effective prevention and control of bleeding episodes in patients with congenital hemophilia A1
Adapted from Jivi Product Monograph and Coyle TE, et al.
Site-specifically PEGylated to reduce clearance and extend half-life while maintaining full biological coagulant activity1–4
Jivi (Antihemophilic Factor [Recombinant, B-domain deleted, PEGylated]) is a recombinant
Factor VIII with an extended half-life.1*
AUC=under the curve.
*Clinical significance has not been established.
